Recombinant human adenovirus type 5 administration for the treatment of malignant ascites or pleural effusion in cancer patients: a meta-analysis.

ABSTRACT:

Objective

H101 (recombinant human adenovirus type 5) has favorable efficacy and safety in cancer patients with malignant ascites (MA) or pleural effusion (MPE). However, a comprehensive evaluation has not yet been conducted. This meta-analysis aimed to comprehensively investigate the efficacy and safety of H101 in these patients.

Methods

The meta-analysis was registered on PROSPERO (ID: CRD420251052407). A comprehensive study search was conducted in PubMed, Web of Science, Cochrane Library, Wan Fang, CNKI, and SinoMed until October 2024. Studies reporting on the remission and safety results in cancer patients with MA/MPE treated with H101 were screened. The overall remission rates (ORRs) of ascites or pleural effusion and adverse reactions were analyzed.

Results

A tot

SUBMITTER: Duan C 

PROVIDER: S-EPMC12483890 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature